Cytek Biosciences (CTKB) Expected to Announce Earnings on Thursday

Cytek Biosciences (NASDAQ:CTKB) is anticipated to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.02 per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Cytek Biosciences Price Performance

CTKB opened at $4.20 on Thursday. Cytek Biosciences has a 52 week low of $2.37 and a 52 week high of $6.18. The stock has a market cap of $537.01 million, a PE ratio of -42.00 and a beta of 1.30. The business has a 50 day moving average of $5.01 and a 200-day moving average of $4.54.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Zacks Research lowered shares of Cytek Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. TD Cowen restated a “buy” rating on shares of Cytek Biosciences in a report on Thursday, January 8th. Piper Sandler lowered their target price on shares of Cytek Biosciences from $8.00 to $7.50 and set an “overweight” rating for the company in a report on Tuesday, November 11th. Morgan Stanley initiated coverage on Cytek Biosciences in a research report on Monday, December 1st. They issued an “equal weight” rating and a $6.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cytek Biosciences in a research report on Monday, December 29th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $5.50.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Boston Partners grew its holdings in shares of Cytek Biosciences by 13,369.4% in the fourth quarter. Boston Partners now owns 5,008,309 shares of the company’s stock worth $25,297,000 after acquiring an additional 4,971,126 shares during the period. Topline Capital Management LLC boosted its position in Cytek Biosciences by 255.7% in the second quarter. Topline Capital Management LLC now owns 5,231,260 shares of the company’s stock worth $17,786,000 after purchasing an additional 3,760,485 shares during the last quarter. Wellington Management Group LLP bought a new stake in shares of Cytek Biosciences during the 3rd quarter valued at about $8,817,000. Millennium Management LLC increased its position in shares of Cytek Biosciences by 269.6% during the 3rd quarter. Millennium Management LLC now owns 3,418,382 shares of the company’s stock valued at $11,862,000 after purchasing an additional 2,493,610 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in shares of Cytek Biosciences by 527.6% in the 4th quarter. Russell Investments Group Ltd. now owns 1,001,127 shares of the company’s stock worth $5,056,000 after purchasing an additional 841,614 shares during the period. Institutional investors own 69.46% of the company’s stock.

About Cytek Biosciences

Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.

The company’s core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters.